| 000 | 01762 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514191520.0 | ||
| 264 | 0 | _c20040720 | |
| 008 | 200407s 0 0 eng d | ||
| 022 | _a0024-3205 | ||
| 024 | 7 |
_a10.1016/j.lfs.2004.01.022 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSasaki, Minoru | |
| 245 | 0 | 0 |
_aLosartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. _h[electronic resource] |
| 260 |
_bLife sciences _cJul 2004 |
||
| 300 |
_a869-80 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAngiotensin II Type 1 Receptor Blockers |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xdrug therapy |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEnalapril _xtherapeutic use |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aKidney Glomerulus _xdrug effects |
| 650 | 0 | 4 |
_aLosartan _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred Strains |
| 650 | 0 | 4 | _aMice, Obese |
| 650 | 0 | 4 |
_aOrgan Size _xdrug effects |
| 650 | 0 | 4 |
_aReceptor, Angiotensin, Type 1 _xphysiology |
| 650 | 0 | 4 | _aWater Supply |
| 700 | 1 | _aUehara, Sayuri | |
| 700 | 1 | _aOhta, Hisashi | |
| 700 | 1 | _aTaguchi, Kazuhiro | |
| 700 | 1 | _aKemi, Masayuki | |
| 700 | 1 | _aNishikibe, Masaru | |
| 700 | 1 | _aMatsumoto, Hiroyoshi | |
| 773 | 0 |
_tLife sciences _gvol. 75 _gno. 7 _gp. 869-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lfs.2004.01.022 _zAvailable from publisher's website |
| 999 |
_c14890360 _d14890360 |
||